<DOC>
	<DOCNO>NCT02148705</DOCNO>
	<brief_summary>This study three-arms study intend demonstrate superiority NexoBrid treatment Gel Vehicle placebo control treatment SOC thermal burn subject . The study objective : 1 . To demonstrate efficacy enzymatic eschar removal NexoBrid provide complete eschar removal compare Gel vehicle , 2 . To demonstrate efficacy enzymatic eschar removal NexoBrid provide earlier complete eschar removal , reduction patient ' surgical burden relate blood loss compare SOC , 3 . To assess safety NexoBrid compare SOC , include demonstration treatment NexoBrid cause unacceptable level harm wound closure outcome long term outcome cosmesis function . Physicians define one Target Wounds ( TWs ) per subject accord TWs definition . All subject ' deep ( DPT FT ) burn comply specify entrance criterion intend receive study treatment per randomize study arm . The randomization procedure initiate Target wound subject define . Patients assign treatment arm 3:3:1 ratio ( NexoBrid : SOC : Gel Vehicle ) . Patients treat way study arm ( NexoBrid , SOC Gel vehicle ) except eschar removal stage perform per randomization study arm . Prior initiation eschar removal treatment , subject medicate appropriate analgesia undergo wound cleanse dress wound antibacterial solution . Following wound cleanse antibacterial treatment , subject undergo eschar removal process per treatment assignment ( NexoBrid , SOC Gel Vehicle , follow randomization ) . Subsequent complete eschar removal , wound assess treated manner , accordance post-eschar removal wound care strategy . Post eschar removal , subject undergo daily vital sign pain assessment , hospital discharge ( HD ) weekly assessment wound progress , wound closure . Following wound closure confirmation visit , subject follow 1 , 3 , 6 , 12 , 18 24 month post wound closure long term outcome evaluation .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety NexoBrid Subjects With Thermal Burns</brief_title>
	<detailed_description />
	<mesh_term>Burns</mesh_term>
	<criteria>Inclusion Criteria Patient level 1 . Males female ; ≥ 18 ≤ 70 year age , 2 . Thermal burn cause fire/flame , scald contact , 3 . Patient total burn area ≥ 3 % DPT / FT , 4 . Patient total burn area ≤ 15 % TBSA ; SPT , DPT and/or FT depth , 5 . Informed consent obtain within 48 hour burn injury , 6 . Patients willing able sign write consent form . Inclusion Criteria Wound level At least one wound ( continuous burn area treat one session ; may include several anatomical area ) patient meet follow criterion : 1 . Wound ≥1 % TBSA ( DPT and/or FT ) ( include face , perineal genital ) , 2 . Wound 's blister removed/unroofed , judged investigator . Exclusion Criteria Patient level 1 . Patients unable follow study procedure follow period , 2 . Modified Baux index ≥ 80 , 3 . Patients burn charred finger , 3rd degree depth possibly devoid circulation , 4 . Patients abrade wound/s treat enzymatic debrider application ( NexoBrid ) exclude study , 5 . Patients electrical , blast chemical burn , 6 . Patients DPT and/or FT facial burn wound flame , flash , explosion &gt; 0.5 % TBSA ( scald contact burn allow ) , 7 . Patients circumferential DPT and/or FT burn define Extremities Risk ( EAR ) , 8 . The following preenrollment dressing : a. Flammacerium , b . Silver Nitrate ( AgNO3 ) , 9 . Patients preenrolment wound cover eschar heavily saturate iodine SSD pseudoeschar ( e.g . pseudoeschar result SSD treatment ) , 10 . Patients preenrollment escharotomy , 11 . Patients diagnosed infection describe Section 11.6.3 study protocol , 12 . Any sign history may indicate smoke inhalation ( e.g . flame burn upper body , flame enclose space , smoke fumes patient mouth nostril , deep flame burn &gt; 0.5 % TBSA face , cough , hoarseness , stridor breathe difficulty include tachypnea possibly relate smoke inhalation , etc . ) , 13 . Pregnant woman ( positive pregnancy test ) nursing mother , 14 . Poorly control diabetes mellitus ( HbA1c &gt; 9 % ) patient know diabetes capture medical history , 15 . Patients BMI great 34.0 kg/m2 , 16 . ASA great 2 ( Appendix 13 ASA classification system ) 17 . Cardiopulmonary disease ( MI within 6 month prior injury , pulmonary hypertension , COPD preexist oxygendependent pulmonary disease , bronchopneumonia , steroid dependent asthma uncontrolled asthma ) , 18 . Preexisting disease interfere circulation ( peripheral vascular disease , edema , lymphedema , surgery regional lymph node , obesity , varicose vein ) , 19 . Any condition would preclude safe participation study add risk basic acute burn trauma ( immunocompromising disease , life threaten trauma , severe preexist coagulation disorder , cardiovascular disorder , pulmonary disorder , liver disorder include post alcoholic abuse impaired function neoplastic disease ) , 20 . Chronic systemic steroid intake , 21 . History allergy and/or know sensitivity pineapple , papaya , Bromelain papain , 22 . Current ( within 12 month prior screen ) suicide attempt , 23 . Mentally incapacitated adult incapable give legal consent ( e.g . dementia , psychiatric patient , etc ) , 24 . Enrollment investigational drug trial within 4 week prior screen , 25 . Current ( within 12 month prior screen ) alcohol ( daily consumption &gt; 3 unit male &gt; 2 unit female ) drug abuse , 26 . Prisoners incarcerate , 27 . Patients might depend clinical study site investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>fire/flame</keyword>
	<keyword>scald</keyword>
	<keyword>contact</keyword>
</DOC>